Explore our thought
Women’s Health: The Opportunity in Gynecology and Beyond
Women’s Health: The Opportunity in Gynecology and Beyond Women’s healthcare and FemTech are garnering increasing attention, yet unmet need remains high, leaving opportunity for investment in an area with significant white space for growth. In this article, we highlight why investment in women’s health is important, where funding gaps lie, and demonstrate the potential for […]
Blogs and publications
Women’s Health: The Opportunity in Gynecology and Beyond
March 8, 2023 • Women’s Health: The Opportunity in Gynecology and Beyond Women’s healthcare and FemTech are garnering increasing attention, yet unmet need remains high, leaving opportunity for investment in an area with significant white space for growth. In this article, we highlight why investment in women’s health is important, where funding gaps lie, and demonstrate the potential for […]
For Patient Engagement solutions looking for an exit, 2023 could be their year
February 15, 2023 • For Patient Engagement solutions looking for an exit, 2023 could be their year After a fraught 2022 that saw a significant slowdown in acquisitions from 2021’s volume and valuation highs, product companies view M&A as a potential strategy in 2023 to enhance their value proposition and achieve efficiencies of scale. Deal volume may rebound moderately […]
5 Misconceptions for MedTech Market Access Strategy
October 19, 2022 • 5 Misconceptions for MedTech Market Access Strategy Market access in MedTech is a complex and rapidly evolving environment, with increasingly intense scrutiny on the costs and benefits of new technologies as the pressure on budgets increases globally. The ability to prepare for and navigate market access strategy is, now more than ever, crucial to the […]
Using the Patient Journey to Understand Health Equity Challenges
September 29, 2022 • Health Equity: Overview of Health Systems and Patient Pathway Unequal healthcare access among different groups leads to less preventative care, and more urgent and intensive procedures. Such disparities in access currently cost the US healthcare system approximately $320 B annually and is projected to grow to as much as $1 trillion annually in 2040. In […]
Key Insights & Takeaways: American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo
August 23, 2022 • The Clinical Chemistry Annual Meeting did not disappoint with great attendance, engaging talks, and some innovative exhibits. After digesting all our notes (and a bit of Chicago’s finest culinary fare) from the busy week, we walked away with five key takeaways: Innovative culture on display If new products and technologies capture your attention, the Clinical […]
Rare Disease Drug Development & Commercialization Learnings, Opportunities & Debates at World Orphan Drug Congress USA 2022
July 21, 2022 • The Kx team attended the World Orphan Drug Congress (WODC) in Boston, MA last week and came away energized from three days of sharing ideas, inspirational stories, and panel discussions. This event brings together the full range of stakeholders who drive and support orphan drug development, regulatory approval, treatment delivery, and patient/caregiver support services. Here […]
Q&A with Kx: Spotlight on AACC 2022
July 6, 2022 • Q&A with Kx: Spotlight on AACC 2022 American Association for Clinical Chemistry (AACC) 2022 Annual Scientific Meeting & Clinical Lab Expo July 24 -28, 2022 McCormick Place Convention Center Chicago, Illinois USA Before they head off to the Windy City for this year’s AACC Annual Scientific Meeting & Clinical Lab Expo, we asked Bob Serrano […]
Cell and Gene Therapy: The Next Frontier in Healthcare
June 5, 2022 • Cell and Gene Therapy (CGT) is one of the most promising new frontiers in advanced therapies with the potential for transformational disease-modifying outcomes. We analyze the state of the Cell & Gene Therapy pipeline and technologies driving growth.
Strategizing for Your First Drug Launch
June 3, 2022 • Strategizing for your First Drug Launch: Supporting late-stage, pre-revenue pharmaceutical companies who are planning to directly commercialize their first product capitalize on these competitive advantages.
Digital Priorities of the C-Suite
March 28, 2022 • Learn how digital health companies enable health system digital transformation while remaining competitive against Big Tech
Home Dialysis: Unlocking New Opportunities in an Evolving Landscape
February 3, 2022 •Download Report
Hot Indications List 2021: Hot MOAs
September 30, 2021 •Download Report
Key Considerations for Rare Disease Due Diligence
July 20, 2021 •Download Report
Six Considerations to Evolve Your Capital Equipment Pricing Strategy
May 10, 2021 • As the world of capital equipment becomes more innovative, manufacturers must find ways to stay competitive, including alternative pricing models. Learn more about the new models and the key considerations manufacturers must evaluate to determine the right fit.
Using Your Product Launch Forecast as a Strategic Tool
April 22, 2021 • Too often commercial planning teams approach revenue forecasting as a required financial exercise rather than a strategic planning activity. Learn how to craft your product launch forecast as a decision-making tool, rather than just a financial tool.
How Understanding Cognitive Bias Can Drive Patient Volumes
January 6, 2021 • Cognitive biases held by both patients and providers can negatively impact treatment. Read our key takeaways on how these biases can drive patient volumes.
Kx’s Four-Step Customer Segmentation Process
November 9, 2020 • Learn how your team can improve your customer segmentation process by expanding the factors you include in your segmentation
Hot Indications List 2020 – Neurology
October 29, 2020 •Download Report
Hot Indications List 2020
October 20, 2020 •Download Report
Why Your Orphan Drug Needs A Global Market Access Strategy
July 9, 2020 • An effective market access strategy for orphan drugs must be globally focused and adaptable to different regions to be effective. Our experts dissect the questions and considerations key to building one.
How Medical Practices Can Keep Patients Safe: COVID-19 Best Strategies
June 9, 2020 • As COVID restrictions are rolled back, medical practices can implement practices to keep both staff and patients safe. Our experts outline COVID-19 best strategies based on direct feedback from physicians.
How Does COVID-19 Change Clinical Pipeline Prioritization?
May 28, 2020 • Our experts break down both the challenges healthcare organizations face due to COVID-19 and the considerations they must analyze as they assess and adapt their strategic pipeline.
Elective Procedures After COVID-19: How To Support Rebounding Demand
May 22, 2020 • Our experts dissect elective procedures COVID-19 restrictions and explore how procedure-focused companies can support rebounding demand.
Should You Do Market Research During COVID-19?
April 22, 2020 • Healthcare leaders are asking: is now a good time to do market research given COVID-19? Our experts answer with an enthusiastic yes. Find out what kinds of research to perform and avoid during the pandemic.
Adapting In COVID-19: A Product Forecasting Framework
April 13, 2020 • With patients depending on healthcare companies for life-changing medications and devices, accurate forecasting to respond to the evolving COVID-19 challenges is paramount. Our framework can help product teams adjust appropriately.
3 Questions To Ask For Launch Planning During COVID-19
March 27, 2020 • Pharmaceuticals and medical device companies must act quickly to adapt product launch plans. See our team’s framework for product managers facing this pandemic.
How Is COVID-19 Impacting Procedure Volume?
March 27, 2020 • Learn how COVID-19 is impacting procedure volume within the orthopedic field and what insights companies in other fields can leverage to adjust their strategic plans.
Hot Indications List 2019
July 9, 2019 •Download Report
Rare Diseases – Patient Advocacy
May 23, 2019 • See how PAGs help patients navigate a complex journey and ultimately seek out life-changing treatments.
Rare Diseases – Stakeholder Education
March 21, 2019 • KOLs and COEs are key stakeholders in the rare disease space and should be top of mind for companies looking to enter the space.
Rare Diseases – Market Access
February 13, 2019 • Learn why a global market access strategy is necessary to maximize the opportunity in rare disease.
Developing a Winning Outpatient Strategy
January 25, 2019 •Download Report
Hot Indications List 2018 – Oncology
June 12, 2018 •Download Report
Hot Indications List 2018
June 12, 2018 •Download Report
Hot Indications List 2017 – Oncology
June 7, 2017 •Download Report
Hot Indications List 2017
February 10, 2017 •Download Report
Delivering Precision Medicine
September 28, 2016 •Download Report
2016 Hot Indications Deep Dive – Oncology
September 3, 2016 •Download Report
2016 Hot Indications Deep Dive – Immunology
June 4, 2016 •Download Report
Hot Indications List 2016
March 1, 2016 •Download Report
Hot Indications List 2015
March 10, 2015 •Download Report
Taking a Fresh Look at Co-Pay Assistance Programs
September 3, 2014 •Download Report